Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Integral Diagnostics Ltd. ( (AU:IDX) ) has shared an update.
Integral Diagnostics Ltd. announced the issuance of 829,926 performance rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX until the restrictions are lifted, potentially impacting employee retention and motivation strategies.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Ltd. operates in the healthcare industry, providing diagnostic imaging services. The company focuses on delivering medical imaging services including X-rays, MRIs, and CT scans, primarily serving the Australian market.
Average Trading Volume: 1,063,185
Technical Sentiment Signal: Buy
Current Market Cap: A$1.01B
See more data about IDX stock on TipRanks’ Stock Analysis page.